Insighta’s core product is its proprietary FRAGMA technology, which detects DNA methylation aberrations in cell-free DNA (cfDNA) in bodily fluids such as blood by identifying fragment patterns associated with cancer cells. The platform enables non-invasive, epigenetics-based early detection of multiple cancers and is described as highly accurate and cost-effective. Insighta has commenced clinical trials in Mainland China, initially targeting liver cancer with plans to expand to lung cancer and to develop tests for additional cancer types. The company aims to expedite commercialization of its cancer detection technology in the next few years. Insighta reports US$80 million in cash reserves, which the article states makes it well-capitalized to fund ongoing trials and development. Tencent’s involvement is expected to bring AI and healthcare expertise to further advance FRAGMA and improve accessibility and cost structures for screening.

Total raised

$30M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2024